Lumen Bioscience

Lumen Bioscience is pioneering a disruptive platform for oral biologic drugs using engineered spirulina, which promises faster, cheaper, and more scalable development compared to traditional cell-culture methods. The company's lead program, LMN-801, is a Phase 2 oral hormone therapy for weight loss, with additional Phase 2/3 programs targeting C. difficile infection and oxalate malabsorption. Backed by $185 million in investment and a robust patent portfolio, Lumen aims to address large, underserved markets by making biologic therapies more accessible and affordable.

Proprietary platform using genetically engineered spirulina (food algae) as a production and delivery system for orally administered therapeutic proteins, antibodies, and enzymes. The process involves engineering the algae, growing it phototrophically, and spray-drying the biomass into shelf-stable capsules.

In obesity, Lumen faces intense competition from large pharmaceutical companies with injectable GLP-1 agonists and oral small molecules. In C. difficile, it competes with other novel antibiotics, microbiome therapies, and toxin-binding antibodies. Its key differentiation is the combination of oral delivery, biologic mechanism, and potentially disruptive low cost.